Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9881 USD | +1.04% | +9.78% | +93.37% |
04-19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
04-18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+93.37% | 184M | |
-3.05% | 90.45B | |
+3.95% | 41.45B | |
-10.39% | 33.57B | |
+60.58% | 25.73B | |
-20.73% | 14.73B | |
-9.00% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- YS Stock
- News YS Biopharma Co., Ltd.
- YS Biopharma Enrolls 1st Subject in Late-Stage Rabies Vaccine Clinical Trial; Shares Rise